{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:44Z","timestamp":1790040344556,"version":"4.0.1"},"reference-count":267,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jtct.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T22:49:10Z","timestamp":1655333350000},"page":"530-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9717-2973","authenticated-orcid":false,"given":"Katherine","family":"Tarlock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Sulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Chewning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Gamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6659-7036","authenticated-orcid":false,"given":"Matthew","family":"Kutny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Horan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap-Jan","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bleakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.06.005_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2006.10.024","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review","volume":"13","author":"Oliansky","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0002","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.005_bib0003","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","article-title":"A new system for grading recommendations in evidence-based guidelines","volume":"323","author":"Harbour","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2022.06.005_bib0004","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.bbmt.2005.06.005","article-title":"The evolution of the evidence-based review: evaluating the science enhances the art of medicine\u2013statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation","volume":"11","author":"Jones","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0005","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0006","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.2009.25.6321","article-title":"Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98","volume":"28","author":"von Neuhoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0007","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0008","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","article-title":"The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial","volume":"118","author":"Burnett","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0009","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0010","first-page":"407","article-title":"Revised risk stratification criteria for children with newly diagnosed acute myeloid leukemia: a report from the Children's Oncology Group","volume":"130","author":"Cooper","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0011","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood-2006-03-009233","article-title":"Clinical implications of FLT3 mutations in pediatric AML","volume":"108","author":"Meshinchi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/leu.2016.177","article-title":"Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group","volume":"31","author":"Manara","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0013","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0014","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.bbmt.2015.10.023","article-title":"Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD","volume":"22","author":"Ho","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0016","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2014.08.008","article-title":"The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia","volume":"21","author":"Schechter","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0017","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0018","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/s41409-020-0936-z","article-title":"Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission","volume":"55","author":"Shouval","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.005_bib0019","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2018-99-113676","article-title":"Distinct co-occurring mutational profiles in acute myeloid leukemia confers prognostic significance in children and young adults with FLT3\/ITD mutations","volume":"132","author":"Tarlock","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2013.04.001","article-title":"Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia","volume":"19","author":"Burke","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0021","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/pbc.24739","article-title":"Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation","volume":"61","author":"Kelly","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0022","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.06.005_bib0023","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0024","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0025","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood-2015-02-629204","article-title":"Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study","volume":"126","author":"Inaba","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0026","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1182\/blood-2016-01-695551","article-title":"Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study","volume":"127","author":"de Rooij","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0027","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3324\/haematol.2011.051714","article-title":"The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study","volume":"97","author":"Klusmann","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.005_bib0028","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the Phase III Children's Oncology Group Trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0029","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/sj.leu.2404233","article-title":"A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies","volume":"20","author":"Slovak","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.12852","article-title":"Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group","volume":"166","author":"Tarlock","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0031","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/leu.2011.229","article-title":"Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis","volume":"26","author":"Ishiyama","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0032","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2013.098517","article-title":"t(6;9)(p22;q34)\/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients","volume":"99","author":"Sandahl","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.005_bib0033","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjh.16433","article-title":"Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission","volume":"189","author":"D\u00edaz-Bey\u00e1","year":"2020","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.005_bib0034","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2021-147576","article-title":"Significant improvements in survival for patients with t(6;9)(p23;q34)\/DEK-NUP214 in contemporary trials with intensification of therapy: a report from the Children's Oncology Group","volume":"138","author":"Tarlock","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0035","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1182\/blood-2006-10-051342","article-title":"Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study","volume":"109","author":"Hasle","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0036","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0037","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","article-title":"NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern","volume":"118","author":"Hollink","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0038","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/blood-2014-04-570929","article-title":"NUP98\/NSD1 and FLT3\/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report","volume":"124","author":"Ostronoff","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0039","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/gcc.22064","article-title":"NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia","volume":"52","author":"Shiba","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0040","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/gcc.22444","article-title":"Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome","volume":"56","author":"Hara","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0041","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","article-title":"An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia","volume":"22","author":"Gruber","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtct.2022.06.005_bib0042","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2012-11-469825","article-title":"CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype","volume":"121","author":"Masetti","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0043","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2014.106526","article-title":"Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002\/01 protocol have an outcome comparable to that of older children","volume":"99","author":"Masetti","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.005_bib0044","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.05.4312","article-title":"Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group","volume":"24","author":"Langebrake","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0045","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2002-10-3064","article-title":"Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia","volume":"101","author":"Sievers","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0046","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0047","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2010.153","article-title":"Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97\/MRC AML12 protocol","volume":"24","author":"van der Velden","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0048","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.14523","article-title":"Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol","volume":"177","author":"Buldini","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0049","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0050","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/bjh.13611","article-title":"Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002\/01 clinical trial","volume":"171","author":"Quarello","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0051","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bmt.1704689","article-title":"Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia","volume":"34","author":"Nemecek","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0052","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1200\/JCO.2008.16.4442","article-title":"Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy","volume":"26","author":"Bunin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0053","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0054","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bmt.2017.3","article-title":"Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience","volume":"52","author":"O'Hare","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0055","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41409-019-0461-0","article-title":"Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia","volume":"54","author":"Okamoto","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0056","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/pbc.22612","article-title":"Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study","volume":"55","author":"Gorman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0057","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2011.11.009","article-title":"Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia","volume":"18","author":"Kobos","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0058","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41409-018-0157-x","article-title":"High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group","volume":"53","author":"Gassas","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0059","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12185-014-1616-9","article-title":"Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol","volume":"100","author":"Nakayama","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0060","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/bjh.14720","article-title":"Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia","volume":"178","author":"Karlsson","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0061","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/MPH.0b013e31816e2342","article-title":"Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission","volume":"30","author":"Fagioli","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0062","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/cncr.22385","article-title":"Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia","volume":"109","author":"Rubnitz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0063","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.leu.2401254","article-title":"Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party","volume":"13","author":"Webb","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0064","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolorflow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0065","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0066","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.9","article-title":"Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML","volume":"49","author":"Anthias","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0067","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0068","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0069","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1038\/bcj.2016.46","article-title":"Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"6","author":"Kayser","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.06.005_bib0070","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0071","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.bbmt.2018.06.010","article-title":"Outcomes of measurable residual disease in pediatric acute myeloid leukemia before and after hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression","volume":"24","author":"Jacobsohn","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0072","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2141.2005.05758.x","article-title":"Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for Blood and Marrow Transplantation","volume":"131","author":"Cesaro","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0073","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.bmt.1705141","article-title":"Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry","volume":"36","author":"Donadieu","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0074","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/bmt.2008.151","article-title":"Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome","volume":"42","author":"Bhatla","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0075","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2013-01-479733","article-title":"Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience","volume":"122","author":"Peffault de Latour","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0076","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2016-09-743112","article-title":"Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study","volume":"129","author":"Mehta","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0077","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.15495","article-title":"Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita","volume":"183","author":"Fioredda","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0078","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1399-3046.2010.01431.x","article-title":"Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita","volume":"15","author":"Nishio","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0079","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.bbmt.2017.06.002","article-title":"Allogeneic hematopoietic cell transplantation using treosulfan-based conditioning for treatment of marrow failure disorders","volume":"23","author":"Burroughs","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0080","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3324\/haematol.2015.138180","article-title":"Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT","volume":"101","author":"Savani","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.005_bib0081","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringden","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0082","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/blood-2013-10-535716","article-title":"Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens","volume":"123","author":"Bitan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0083","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/pbc.25389","article-title":"Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and\/or busulfan in acute myeloid leukemia in Japanese children and adolescents","volume":"62","author":"Ishida","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0084","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0085","doi-asserted-by":"crossref","first-page":"483e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27:","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.005_bib0086","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.bbmt.2018.04.025","volume":"24","author":"Nemecek","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0087","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/bloodadvances.2021005224","article-title":"Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen","volume":"6","author":"Versluijs","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.005_bib0088","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbmt.2016.11.022","volume":"23","author":"Lucchini","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0089","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41409-020-01201-w","article-title":"Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens","volume":"56","author":"Versluys","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0090","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3324\/haematol.2020.249458","article-title":"Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children","volume":"106","author":"Dandoy","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.005_bib0091","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bmt.2013.185","article-title":"Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"49","author":"de Berranger","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0092","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.bbmt.2015.08.011","volume":"21","author":"Ishida","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0093","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"Nagler","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0094","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbmt.2015.10.024","article-title":"Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in acute myeloid leukemia","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0095","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0096","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.bmt.1705710","article-title":"Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies","volume":"40","author":"Ferry","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0097","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2002-07-2231","article-title":"Nonmalignant late effects after allogeneic stem cell transplantation","volume":"101","author":"Soci\u00e9","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0098","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1200\/JCO.2014.56.2223","article-title":"Cognitive outcome after pediatric stem-cell transplantation: impact of age and total-body irradiation","volume":"32","author":"Willard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0099","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.2000.18.2.348","article-title":"New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia","volume":"18","author":"Soci\u00e9","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0100","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood-2010-01-261958","article-title":"Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors","volume":"116","author":"Shaw","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0101","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/petr.12475","article-title":"Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: multicenter experience in China","volume":"19","author":"Tang","year":"2015","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0102","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00277-014-2213-y","article-title":"Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia","volume":"94","author":"Zheng","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0103","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1399-3046.2008.00997.x","article-title":"Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission","volume":"13","author":"Lee","year":"2009","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0104","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1182\/bloodadvances.2018025908","article-title":"The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.005_bib0105","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.bbmt.2016.08.004","article-title":"The impact of donor type on long-term health status and quality of life after allogeneic hematopoietic stem cell transplantation for childhood acute leukemia: a Leucemie de l'Enfant et de L'Adolescent Study","volume":"22","author":"Visentin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0106","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.005_bib0107","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3109\/10428194.2015.1102241","article-title":"The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission","volume":"57","author":"Zheng","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.06.005_bib0108","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/bmt.2009.93","article-title":"Long-term outcome of cord blood transplantation from unrelated donors as an initial transplantation procedure for children with AML in Japan","volume":"45","author":"Isoyama","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0109","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbmt.2006.05.008","article-title":"Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation","volume":"12","author":"Parkman","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0110","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0111","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.005_bib0112","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0113","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.bbmt.2016.09.004","article-title":"Unmanipulated haploidentical hematopoietic stem cell transplantation in first complete remission can abrogate the poor outcomes of children with acute myeloid leukemia resistant to the first course of induction chemotherapy","volume":"22","author":"Mo","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0114","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.2017.187450","article-title":"Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT","volume":"104","author":"Brissot","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.005_bib0115","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/pbc.24524","article-title":"PBSCT is associated with poorer survival and increased chronic GvHD than BMT in Japanese paediatric patients with acute leukaemia and an HLA-matched sibling donor","volume":"60","author":"Shinzato","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0116","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.bbmt.2018.08.010","article-title":"Bone marrow versus peripheral blood from unrelated donors for children and adolescents with acute leukemia","volume":"24","author":"St Martin","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0117","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbmt.2019.07.025","article-title":"Allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation for hematologic malignancies in children: a systematic review and meta-analysis","volume":"26","author":"Shimosato","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0118","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.005_bib0119","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.bbmt.2017.07.004","article-title":"A chemotherapy-only regimen of busulfan, melphalan, and fludarabine, and rabbit antithymocyte globulin followed by allogeneic T-cell depleted hematopoietic stem cell transplantations for the treatment of myeloid malignancies","volume":"23","author":"Spitzer","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0120","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","article-title":"Unrelated donor vs HLA-haploidentical alpha\/beta T-cell- and B-cell-depleted HSCT in children with acute leukemia","volume":"132","author":"Bertaina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0121","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts","volume":"125","author":"Bleakley","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2022.06.005_bib0122","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41409-021-01259-0","article-title":"Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT","volume":"56","author":"Ruggeri","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0123","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2014-09-599993","article-title":"Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality","volume":"125","author":"Mancusi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0124","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1182\/blood-2008-06-164103","article-title":"Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity","volume":"113","author":"Pende","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0125","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.005_bib0126","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/bloodadvances.2019001284","article-title":"Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia","volume":"4","author":"Verneris","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.005_bib0127","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.bbmt.2019.12.723","article-title":"A phase 2 trial of KIR-mismatched unrelated donor transplantation using in vivo T cell depletion with antithymocyte globulin in acute myelogenous leukemia: Children's Oncology Group AAML05P1 Study","volume":"26","author":"Davies","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0128","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood-2003-01-0091","article-title":"Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors","volume":"102","author":"Giebel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0129","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1182\/blood-2007-01-065383","article-title":"Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT","volume":"109","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0130","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.bbmt.2016.04.007","article-title":"Killer cell immunoglobulin-like receptor-ligand matching and outcomes after unrelated cord blood transplantation in acute myeloid leukemia","volume":"22","author":"Rocha","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0131","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/leu.2011.267","article-title":"Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report","volume":"26","author":"Creutzig","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0132","doi-asserted-by":"crossref","first-page":"e27089","DOI":"10.1002\/pbc.27089","article-title":"Acute myelogenous leukemia in adolescents and young adults","volume":"65","author":"Creutzig","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0133","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1002\/cncr.27659","article-title":"Treatment outcome in older patients with childhood acute myeloid leukemia","volume":"118","author":"Rubnitz","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0134","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12185-015-1825-x","article-title":"Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols","volume":"102","author":"Tomizawa","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0135","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1002\/cncr.28342","article-title":"Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent\/young adult and younger patients: a report from the Children's Oncology Group","volume":"119","author":"Canner","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0136","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2011.10.031","article-title":"Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia","volume":"18","author":"Majhail","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0137","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.bbmt.2017.05.009","article-title":"Allogeneic hematopoietic stem cell transplantation for adolescents and young adults with acute myeloid leukemia","volume":"23","author":"Tomizawa","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0138","first-page":"608","article-title":"Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891","volume":"91","author":"Lange","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0139","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0140","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2015-05-567859","article-title":"The biology of pediatric acute megakaryoblastic leukemia","volume":"126","author":"Gruber","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0141","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0142","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","article-title":"Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial","volume":"129","author":"Taub","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0143","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/pbc.25789","article-title":"Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down syndrome: a nationwide prospective study in Japan","volume":"63","author":"Taga","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0144","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2003.08.060","article-title":"Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891","volume":"21","author":"Gamis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0145","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2013.02.017","article-title":"Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome","volume":"19","author":"Hitzler","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0146","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/pbc.24883","article-title":"Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome","volume":"61","author":"Muramatsu","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0147","doi-asserted-by":"crossref","first-page":"26664","DOI":"10.1002\/pbc.26664","article-title":"Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups","volume":"64","author":"Creutzig","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0148","doi-asserted-by":"crossref","first-page":"26520","DOI":"10.1002\/pbc.26520","article-title":"Extramedullary leukemia in children with acute myeloid leukemia: a population-based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO)","volume":"64","author":"St\u00f8ve","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0149","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MPH.0000000000001034","article-title":"Acute myeloid leukemia with central nervous system involvement in children: experience from the French Protocol Analysis ELAM02","volume":"40","author":"Felix","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0150","doi-asserted-by":"crossref","first-page":"26612","DOI":"10.1002\/pbc.26612","article-title":"Central nervous system disease in pediatric acute myeloid leukemia: a report from the Children's Oncology Group","volume":"64","author":"Johnston","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0151","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.bbmt.2014.09.001","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement","volume":"20","author":"Aoki","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0152","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/bmt.2015.82","article-title":"Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome","volume":"50","author":"Goyal","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0153","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00043426-200310000-00004","article-title":"Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group","volume":"25","author":"Dusenbery","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0154","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1200\/JCO.2007.15.6315","article-title":"Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC","volume":"26","author":"Chevallier","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0155","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.leu.2404491","article-title":"Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients","volume":"21","author":"Pileri","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0156","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/pbc.21390","article-title":"Role of total skin electron beam therapy for leukemia cutis in pediatric patients","volume":"50","author":"Pepek","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0157","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/MPH.0b013e3182678e9f","article-title":"Total skin electron beam radiation in a pediatric patient with leukemia cutis: a case report","volume":"34","author":"Majd","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0158","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","article-title":"How I treat extramedullary acute myeloid leukemia","volume":"118","author":"Bakst","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0159","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12185-018-2492-5","article-title":"Clinical characteristics of pediatric patients with myeloid sarcoma without bone marrow involvement in Japan","volume":"108","author":"Taga","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0160","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/pbc.25238","article-title":"Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina","volume":"62","author":"Basquiera","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0161","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/pbc.24390","article-title":"Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS","volume":"60","author":"Smith","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0162","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/leu.2010.297","article-title":"Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study","volume":"25","author":"Strahm","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0163","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0164","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbmt.2014.12.003","article-title":"Hematopoietic stem cell transplantation in children with refractory cytopenia of childhood: single-center experience using high-dose cytarabine containing myeloablative and aplastic anemia oriented reduced-intensity conditioning regimens","volume":"21","author":"Inagaki","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0165","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/sj.bmt.1705730","article-title":"Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood","volume":"40","author":"Strahm","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0166","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2012.45.9719","article-title":"Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia","volume":"31","author":"Ayas","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0167","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.12634","article-title":"Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia","volume":"164","author":"Mitchell","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0168","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2352-3026(19)30206-6","article-title":"Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study","volume":"7","author":"Myers","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0169","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.bbmt.2020.04.029","article-title":"Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome","volume":"26","author":"Myers","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2008.11.037","article-title":"Hematopoietic stem cell transplantation for bone marrow failure syndromes in children","volume":"15","author":"Myers","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0171","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood-2017-09-765214","article-title":"How I treat myelodysplastic syndromes of childhood","volume":"131","author":"Locatelli","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0172","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","article-title":"Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents","volume":"127","author":"Wlodarski","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0173","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0174","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2011.64","article-title":"Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein alpha from hematopoietic cells in a family with AML","volume":"25","author":"Stelljes","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pbc.21157","article-title":"Toxicity and outcome of children with treatment related acute myeloid leukemia","volume":"50","author":"Tabori","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0176","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.V100.2.427","article-title":"Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation","volume":"100","author":"Barnard","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0177","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3324\/haematol.2008.000927","article-title":"Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation","volume":"94","author":"Kr\u00f6ger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.005_bib0178","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0179","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bbmt.2013.11.031","article-title":"Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia","volume":"20","author":"Yoshimi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0180","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/MPH.0b013e3181ba43dc","article-title":"Pediatric therapy-related myelodysplastic syndrome\/acute myeloid leukemia: the MD Anderson Cancer Center experience","volume":"31","author":"Aguilera","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0181","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/pbc.20596","article-title":"Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome","volume":"47","author":"Woodard","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0182","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2016.71.6183","article-title":"Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the Children's Oncology Group Phase III historically controlled trial AAML0631","volume":"35","author":"Kutny","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0183","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 Trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0184","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","article-title":"Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group AAML1331 Trial","volume":"8","author":"Kutny","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0185","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/bmt.2016.96","article-title":"Autologous transplant remains the preferred therapy for relapsed APL in CR2","volume":"51","author":"Ganzel","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0186","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2009.07.010","article-title":"Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen","volume":"15","author":"Thirugnanam","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0187","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/leu.2015.12","article-title":"Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet","volume":"29","author":"Lengfelder","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0188","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2014.03.025","article-title":"Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission","volume":"20","author":"Holter Chakrabarty","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0189","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bbmt.2008.04.015","article-title":"Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia","volume":"14","author":"Dvorak","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0190","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2005.03.127","article-title":"Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group","volume":"23","author":"de Botton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0191","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood-2004-05-1971","article-title":"GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children","volume":"106","author":"Testi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0192","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/pbc.21614","article-title":"Mobilization of PML-RARA negative blood stem cells and salvage with autologous peripheral blood stem cell transplantation in children with relapsed acute promyelocytic leukemia","volume":"51","author":"Termuhlen","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0193","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.bmt.1704676","article-title":"Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood","volume":"34","author":"Bourquin","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0194","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41409-019-0438-z","article-title":"Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children","volume":"54","author":"Dahlberg","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0195","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc1365","article-title":"Molecules and mechanisms of the graft-versus-leukaemia effect","volume":"4","author":"Bleakley","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0196","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.imbio.2013.10.008","article-title":"CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT","volume":"219","author":"Steger","year":"2014","journal-title":"Immunobiology"},{"key":"10.1016\/j.jtct.2022.06.005_bib0197","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood-2006-05-021535","article-title":"Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia","volume":"108","author":"Montagna","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0198","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00277-017-3204-6","article-title":"Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia","volume":"97","author":"Yang","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0199","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0200","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1704321","article-title":"Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children","volume":"33","author":"Gorczy\u00f1ska","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0201","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.bbmt.2011.03.006","article-title":"Variation in management of immune suppression after allogeneic hematopoietic cell transplantation","volume":"17","author":"Pidala","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0202","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0203","first-page":"975","article-title":"Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation","volume":"18","author":"Porter","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0204","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.bmt.1702726","article-title":"Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease","volume":"27","author":"de Lima","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0205","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0206","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15691","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"18","author":"Schmid","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0207","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bmt.1704444","article-title":"Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective","volume":"33","author":"Bader","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0208","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjh.14008","article-title":"Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?","volume":"173","author":"Pichler","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0209","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/blood-2011-04-348805","article-title":"Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation","volume":"118","author":"Rettinger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0210","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0211","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0212","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/bmt.2011.15","article-title":"Early allo-SCT for AML with a complex aberrant karyotype\u2013results from a prospective pilot study","volume":"47","author":"Schmid","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0213","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bbmt.2013.03.001","article-title":"Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose","volume":"19","author":"Bar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0214","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/bmt.2016.326","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML","volume":"52","author":"Legrand","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0215","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2022.06.005_bib0216","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0217","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0218","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"2","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.06.005_bib0219","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood-2017-07-791608","article-title":"Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse","volume":"131","author":"Dossa","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0220","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbmt.2019.03.027","article-title":"Donor-derived cytokine-induced killer cell infusion as consolidation after nonmyeloablative allogeneic transplantation for myeloid neoplasms","volume":"25","author":"Narayan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0221","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0222","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-019-0564-6","article-title":"A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia","volume":"7","author":"Nguyen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0223","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.17751","article-title":"Adoptive immunotherapy with double-bright (CD56(bright) \/CD16(bright)) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study","volume":"195","author":"Silla","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0224","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2022.06.005_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101104","article-title":"How close are we to CAR T-cell therapy for AML?","volume":"32","author":"Gill","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0226","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T cells for the therapy of acute myeloid leukemia","volume":"27","author":"Gomes-Silva","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2022.06.005_bib0227","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0228","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2022.06.005_bib0229","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"3","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0230","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/pbc.25437","article-title":"Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3\/ITD acute myeloid leukemia","volume":"62","author":"Tarlock","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0231","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejca.2017.09.016","article-title":"Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation","volume":"86","author":"Metzelder","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0232","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0233","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.bbmt.2019.04.018","article-title":"Sorafenib therapy is associated with improved outcomes for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Xuan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0234","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.005_bib0235","article-title":"The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow","volume":"13","author":"Lange","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2022.06.005_bib0236","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nm0418-526c","article-title":"Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.06.005_bib0237","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0238","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0239","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/cncr.30680","article-title":"Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia","volume":"123","author":"Battipaglia","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0240","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0241","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0242","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: a report from the Children's Oncology Group Protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0243","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2019.09.023","article-title":"A prospective study of peritransplant sorafenib for patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic transplantation","volume":"26","author":"Pratz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0244","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0245","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0246","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.005_bib0247","first-page":"1766","article-title":"Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2032-deoxycytidine","volume":"54","author":"Weber","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtct.2022.06.005_bib0248","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0249","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML After HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0250","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/bmt.2013.233","article-title":"Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT","volume":"49","author":"Tessoulin","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0251","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bmt.2009.266","article-title":"5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis","volume":"45","author":"Czibere","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0252","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.005_bib0253","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA Trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0254","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00277-017-3185-5","article-title":"Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"97","author":"Schroeder","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0255","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1080\/10428194.2018.1443334","article-title":"Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies","volume":"59","author":"Maples","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.06.005_bib0256","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.005_bib0257","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.07.010","article-title":"Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation","volume":"49","author":"Ghobadi","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2022.06.005_bib0258","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0259","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2018.07.005","article-title":"Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation","volume":"72","author":"Sommer","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2022.06.005_bib0260","doi-asserted-by":"crossref","first-page":"839.e1","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.005_bib0261","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.06.005_bib0262","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.005_bib0263","doi-asserted-by":"crossref","first-page":"e27284","DOI":"10.1002\/pbc.27284","article-title":"Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia","volume":"65","author":"Tamura","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0264","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bbmt.2003.08.003","article-title":"Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia","volume":"9","author":"Meshinchi","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0265","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/pbc.25866","article-title":"Role of second transplantation for children with acute myeloid leukemia following posttransplantation relapse","volume":"63","author":"Taga","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.06.005_bib0266","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","article-title":"Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study","volume":"24","author":"Yaniv","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.005_bib0267","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:05:41Z","timestamp":1763003141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722013665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":267,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2666636722013665"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.06.005","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}